Certuity LLC Acquires Shares of 20,053 Incyte Corporation $INCY

Key Points

• Certuity LLC acquired a new stake of 20,053 shares of Incyte (NASDAQ:INCY) in Q4, valued at approximately $1.98 million.
• Incyte reported Q4 EPS of $1.80, missing the $1.96 consensus, while revenue was $1.51 billion, beating expectations and rising 27.8% year‑over‑year.
• Insider Pablo J. Cagnoni sold 18,667 shares at an average of $96.50 (≈$1.80M) under a Rule 10b5‑1 plan; institutional investors own about 96.97% of the stock and insiders own 17.8%.

Certuity LLC acquired a new stake in shares of Incyte Corporation (NASDAQ:INCY - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 20,053 shares of the biopharmaceutical company's stock, valued at approximately $1,981,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Bank of Nova Scotia increased its position in Incyte by 0.7% during the 2nd quarter. Bank of Nova Scotia now owns 17,041 shares of the biopharmaceutical company's stock valued at $1,160,000 after purchasing an additional 124 shares during the period. Atlantic Edge Private Wealth Management LLC increased its position in Incyte by 0.9% during the 3rd quarter. Atlantic Edge Private Wealth Management LLC now owns 14,556 shares of the biopharmaceutical company's stock valued at $1,235,000 after purchasing an additional 125 shares during the period. Perbak Capital Partners LLP increased its position in Incyte by 2.5% during the 3rd quarter. Perbak Capital Partners LLP now owns 5,298 shares of the biopharmaceutical company's stock valued at $449,000 after purchasing an additional 129 shares during the period. Savvy Advisors Inc. increased its position in Incyte by 2.6% during the 4th quarter. Savvy Advisors Inc. now owns 5,339 shares of the biopharmaceutical company's stock valued at $527,000 after purchasing an additional 133 shares during the period. Finally, Haven Capital Group Inc. increased its position in Incyte by 0.8% during the 4th quarter. Haven Capital Group Inc. now owns 17,985 shares of the biopharmaceutical company's stock valued at $1,776,000 after purchasing an additional 144 shares during the period. 96.97% of the stock is owned by hedge funds and other institutional investors.

Incyte Stock Performance

Shares of INCY stock opened at $95.71 on Tuesday. Incyte Corporation has a one year low of $57.77 and a one year high of $112.29. The company's 50-day moving average is $95.99 and its 200 day moving average is $98.66. The company has a market capitalization of $19.05 billion, a price-to-earnings ratio of 14.93, a price-to-earnings-growth ratio of 0.75 and a beta of 0.85. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.25 and a current ratio of 3.32.

Incyte (NASDAQ:INCY - Get Free Report) last announced its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.80 EPS for the quarter, missing the consensus estimate of $1.96 by ($0.16). Incyte had a net margin of 25.03% and a return on equity of 26.34%. The firm had revenue of $1.51 billion for the quarter, compared to analysts' expectations of $1.35 billion. During the same period last year, the company posted $1.43 earnings per share. The business's revenue for the quarter was up 27.8% compared to the same quarter last year. Sell-side analysts expect that Incyte Corporation will post 6.52 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. The Goldman Sachs Group reissued a "neutral" rating and set a $90.00 price objective on shares of Incyte in a research report on Thursday, January 8th. Barclays reaffirmed an "overweight" rating on shares of Incyte in a research report on Tuesday, March 24th. Jefferies Financial Group downgraded shares of Incyte from a "buy" rating to a "hold" rating and reduced their target price for the stock from $120.00 to $94.00 in a research report on Monday, March 16th. Weiss Ratings raised shares of Incyte from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, April 1st. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $135.00 target price on shares of Incyte in a research report on Wednesday, April 15th. Ten research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $104.89.

Insider Buying and Selling

In related news, insider Pablo J. Cagnoni sold 18,667 shares of the stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $96.50, for a total transaction of $1,801,365.50. Following the sale, the insider directly owned 262,692 shares of the company's stock, valued at approximately $25,349,778. This represents a 6.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 17.80% of the company's stock.

Incyte Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company's research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company's flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.